203 related articles for article (PubMed ID: 18288097)
1. Vitamin D receptor activation and survival in chronic kidney disease.
Kovesdy CP; Kalantar-Zadeh K
Kidney Int; 2008 Jun; 73(12):1355-63. PubMed ID: 18288097
[TBL] [Abstract][Full Text] [Related]
2. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
Sprague SM; Coyne D
Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
5. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
6. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
Toussaint ND; Damasiewicz MJ
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
[TBL] [Abstract][Full Text] [Related]
7. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
Tanaka H; Komaba H; Fukagawa M
Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
[TBL] [Abstract][Full Text] [Related]
8. The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Arcidiacono MV; Yang J; Fernandez E; Dusso A
Nephrol Dial Transplant; 2015 Mar; 30(3):423-33. PubMed ID: 25294851
[TBL] [Abstract][Full Text] [Related]
9. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
10. CKD-MBD: an endless story.
Brancaccio D; Cozzolino M
J Nephrol; 2011; 24 Suppl 18():S42-8. PubMed ID: 21623582
[TBL] [Abstract][Full Text] [Related]
11. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
Wetmore JB; Quarles LD
Nat Clin Pract Nephrol; 2009 Jan; 5(1):24-33. PubMed ID: 18957950
[TBL] [Abstract][Full Text] [Related]
12. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
Andress DL
Kidney Int; 2006 Jan; 69(1):33-43. PubMed ID: 16374421
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
17. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Shinaberger CS; Kopple JD; Kovesdy CP; McAllister CJ; van Wyck D; Greenland S; Kalantar-Zadeh K
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1769-76. PubMed ID: 18701614
[TBL] [Abstract][Full Text] [Related]
18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
20. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
Fukagawa M; Komaba H; Kakuta T
Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
